Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Opalka

Showing results (21-30 of 68) with videos related to

Pageof 7
Sort By:
Intervirology|January 1, 1992
The transformation-defective adenovirus 12 host range mutant CS-1 lacks the E1a-specific 9.5S mRNA and contains a second deletion in E1bB Opalka, M Reith-Witowski, A Roy, et al.
European Journal of Haematology|January 1, 1996
Prognostic impact of interferon alpha-induced cytogenetic remission in chronic myelogenous leukaemia: long-term follow-upO Kloke, N Niederle, B Opalka, et al.
Seminars in Oncology|June 1, 1987
Interferon alfa-2b in the treatment of chronic myelogenous leukemiaN Niederle, O Kloke, R Osieka, et al.
Cancer Gene Therapy|August 5, 2000
Transformation-defective adenovirus 5 E1A mutants exhibit antioncogenic properties in human BLM melanoma cellsA Dickopp, H Esche, G Swart, et al.
Leukemia Research|September 1, 1992
No correlation between site of breakpoint in the BCR gene and platelet counts in Philadelphia chromosome-positive CMLB Opalka, U B Wandl, O Kloke, et al.
Blood|October 1, 1992
No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemiaB Opalka, U B Wandl, R Stutenkemper, et al.
Cancer Genetics and Cytogenetics|July 2, 1998
Frequency of clonal B lymphocytes in chronic myelogenous leukemia evaluated by fluorescence in situ hybridizationA al-Amin, K Lennartz, V Runde, et al.
Blood|July 9, 1999
The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrowA H Elmaagacli, D W Beelen, B Opalka, et al.
Annals of Hematology|September 14, 2000
The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stageA H Elmaagacli, D W Beelen, B Opalka, et al.
Leukemia & Lymphoma|January 1, 1993
Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studiesN Niederle, O Kloke, U B Wandl, et al.
Pageof 7

Showing results (21-30 of 68) with videos related to

Sort By:
Pageof 7
Intervirology|January 1, 1992
The transformation-defective adenovirus 12 host range mutant CS-1 lacks the E1a-specific 9.5S mRNA and contains a second deletion in E1bB Opalka, M Reith-Witowski, A Roy, et al.
European Journal of Haematology|January 1, 1996
Prognostic impact of interferon alpha-induced cytogenetic remission in chronic myelogenous leukaemia: long-term follow-upO Kloke, N Niederle, B Opalka, et al.
Seminars in Oncology|June 1, 1987
Interferon alfa-2b in the treatment of chronic myelogenous leukemiaN Niederle, O Kloke, R Osieka, et al.
Cancer Gene Therapy|August 5, 2000
Transformation-defective adenovirus 5 E1A mutants exhibit antioncogenic properties in human BLM melanoma cellsA Dickopp, H Esche, G Swart, et al.
Leukemia Research|September 1, 1992
No correlation between site of breakpoint in the BCR gene and platelet counts in Philadelphia chromosome-positive CMLB Opalka, U B Wandl, O Kloke, et al.
Blood|October 1, 1992
No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemiaB Opalka, U B Wandl, R Stutenkemper, et al.
Cancer Genetics and Cytogenetics|July 2, 1998
Frequency of clonal B lymphocytes in chronic myelogenous leukemia evaluated by fluorescence in situ hybridizationA al-Amin, K Lennartz, V Runde, et al.
Blood|July 9, 1999
The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrowA H Elmaagacli, D W Beelen, B Opalka, et al.
Annals of Hematology|September 14, 2000
The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stageA H Elmaagacli, D W Beelen, B Opalka, et al.
Leukemia & Lymphoma|January 1, 1993
Long-term treatment of chronic myelogenous leukemia with different interferons: results from three studiesN Niederle, O Kloke, U B Wandl, et al.
Pageof 7